Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

65.45
-0.8000-1.21%
Post-market: 65.450.00000.00%19:30 EDT
Volume:1.74M
Turnover:114.39M
Market Cap:9.22B
PE:-28.66
High:66.80
Open:66.80
Low:65.09
Close:66.25
52wk High:95.49
52wk Low:34.38
Shares:140.86M
Float Shares:122.00M
Volume Ratio:0.85
T/O Rate:1.43%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:19.80
PE(LYR):-5,367.83

Loading ...

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 Yosemite Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

THOMSON REUTERS
·
Jul 27

Arrowhead Pharmaceuticals - Yosemite Phase 3 Study Completion Anticipated in Mid-2027

THOMSON REUTERS
·
Jul 27

Arrowhead Pharmaceuticals is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jul 27

Arrowhead price target raised to $126 from $110 at Piper Sandler

TIPRANKS
·
Jul 23

Arrowhead Pharmaceuticals (ARWR) Is Up 23.5% After Strong Plozasiran Phase 3 Data in Severe Hypertriglyceridemia

Simply Wall St.
·
Jul 23

U.S. Research Roundup-alphabet, IBM, Tesla

Reuters
·
Jul 23

Arrowhead Pharmaceuticals : Piper Sandler Raises Target Price to $126 from $110

THOMSON REUTERS
·
Jul 23

NASDAQ Net Change Percentage Gainers & Losers

Dow Jones
·
Jul 23

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires Live
·
Jul 23

Arrowhead Pharmaceuticals is Maintained at Buy by Chardan Capital

Dow Jones
·
Jul 23

Top Midday Gainers

MT Newswires Live
·
Jul 23

Arrowhead Pharma Shares Rise After Positive Results for Triglyceride Drug Plozasiran Trials

Dow Jones
·
Jul 23

Arrowhead price target raised to $115 from $90 at Chardan

TIPRANKS
·
Jul 23

Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results

TIPRANKS
·
Jul 23

Arrowhead rises 23.4%

TIPRANKS
·
Jul 23

Analysts Are Bullish on These Healthcare Stocks: Arrowhead Pharmaceuticals (ARWR), Otsuka Holdings Co (OTSKY)

TIPRANKS
·
Jul 22

U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma

Reuters
·
Jul 22

Movement Alert|Arrowhead Pharmaceuticals Rises 19.25% in Regular Trading, Core Pipeline Plozasiran Achieves Key Late-Stage Trial Endpoints

Market Focus
·
Jul 22

Arrowhead Pharmaceuticals Shares up 18.1% Premarket After Blood-fat Drug Meets Late-stage Trial Goals

THOMSON REUTERS
·
Jul 22

Arrowhead Rises After Blood-fat Drug Meets Late-stage Trial Goals

Reuters
·
Jul 22